DexCom, Inc. (DXCM) Showcases Next-Gen CGM Features at EASD 2025

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. DexCom, Inc. is one of them.

DexCom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM) systems, continues to advance diabetes care with its flagship G6 and G7 devices, which provide real-time glucose tracking and data sharing. At EASD 2025, the company highlighted upcoming features aimed at improving health outcomes and cost-effectiveness, reinforcing its innovation strategy in biosensing technology. These developments have kept DXCM among the best healthcare stocks, despite recent challenges.

Financial performance remains strong, with second-quarter 2025 revenue rising 15.2% year-over-year and earnings per share beating analyst estimates. Analysts maintain a moderate to strong buy consensus on DXCM, with price targets nearing $100, citing robust demand for its CGM systems.

DexCom, Inc. (DXCM) Showcases Next-Gen CGM Features at EASD 2025

However, September brought challenges after a report alleged unauthorized design changes in the G7 system, linking the issue to severe safety risks, including hospitalizations and deaths. The controversy sparked an 11.76% stock drop and prompted a class action investigation by Pomerantz LLP into potential securities fraud claims.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.